Steven E. Kahn

Consent for genetics studies among clinical trial participants: findings from Action for Health in Diabetes (Look AHEAD)

T. Wadden, A. Kriska, M. Nevitt, 2006, Clinical trials.

Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes

G. Bray, T. Wadden, C. Lewis, 2014, Diabetes Care.

Common variants in genes encoding adiponectin (ADIPOQ) and its receptors (ADIPOR1/2), adiponectin concentrations, and diabetes incidence in the Diabetes Prevention Program

T. Spector, K. Jablonski, J. Florez, 2012, Diabetic medicine : a journal of the British Diabetic Association.

Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program.

E. Barrett-Connor, J. Florez, W. Knowler, 2015, The Journal of clinical endocrinology and metabolism.

Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans.

P. Wahl, R. Schwartz, S. Kahn, 1998, Diabetes.

The Pro12Ala variant at the peroxisome proliferator-activated receptor γ gene and change in obesity-related traits in the Diabetes Prevention Program

D. Altshuler, K. Jablonski, J. Florez, 2007, Diabetologia.

Implications of Look AHEAD for clinical trials and clinical practice

C. Champagne, T. Wadden, A. Kriska, 2014, Diabetes, obesity & metabolism.